BMO Capital analyst Kostas Biliouris downgraded Precision BioSciences to Market Perform from Outperform with a price target of $4, down from $7. The firm feels the company’s decision to deprioritize its in vivo pipeline while focusing on the development of ex vivo programs transitions the stock into a "show me" story, as the firm’s/investor conviction around the ex vivo platform "remains low until we see promising late-stage data."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DTIL: